– August 1, 2003
August 1, 2003
View Issues
-
Practicability and Acute Hematological Toxicity of 2- and 3-Weekly CHOP and CHOEP Chemotherapy for Aggressive NHL
Since the introduction of the 3-weekly CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) chemotherapy 25 years ago, many efforts have been undertaken to improve the efficacy of multicycle polychemotherapy for patients with aggressive lymphoma. -
Platinum-Paclitaxel As Second-Line Chemotherapy for Relapsed Ovarian Cancer
There has been some controversy on the role of taxanes in combination with platinum for the treatment of ovarian cancer. In the current report, patients who relapsed after a disease-free interval of 6 months or more were randomized in 2 large, multicenter trials conducted in Europe to receive either platinum (or typical platinum-based regimens) or paclitaxel plus platinum. -
Reduced Cardiac Risk for Breast Cancer Survivors
Women who survive breast cancer may be at a lower risk of developing coronary artery disease compared with women without a history of breast cancer. -
Isolated Supraclavicular Recurrence of Breast Cancer
The development of an isolated supraclavicular node recurrence of breast cancer after primary surgical resection (including axillary node dissection) was found, upon review of the tumor registries of 8 community hospitals in The Netherlands, to occur very uncommonly (less than 1%). Examination of clinical outcomes for these patients indicates that isolated supraclavicular recurrence is an antecedent of disseminated disease, in that, even with local control (as achieved by radiation therapy), the great majority of patients soon develop systemic disease. -
Radiation Therapy With or Without Extrafascial Hysterectomy for Bulky Stage IB Cervical Carcinoma
Following radiation therapy, adjuvant extrafascial hysterectomy decreased the risk of relapse for patients with bulky stage IB cervical cancer without improving survival. -
Pharmacology Watch: Nasally Administered Flu Vaccine Comes to United States
The FDA has approved the first nasally administered flu vaccine to be marketed in this country. Medimmunes FluMist is also the first influenza vaccine to use live virus.